The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)] (Q80156775)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15175844%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

title

The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15175844%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15175844%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Etah S Kurland

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15175844%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Beverly Diamond

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15175844%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Donald J McMahon

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15175844%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Felicia Cosman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15175844%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

John P Bilezikian

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15175844%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

3 June 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15175844%20AND%20SRC:MED&resulttype=core&format=json

Osteoporosis International

29 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15175844%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15175844%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15175844%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

992-997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15175844%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00198-004-1636-z

29 December 2019

exact match

0 references

cites work

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

1 reference

12 December 2020

Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal

1 reference

12 December 2020

Withdrawal of parathyroid hormone treatment causes rapid resorption of newly formed vertebral cancellous and endocortical bone in old rats

1 reference

12 December 2020

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

1 reference

12 December 2020

Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.

1 reference

12 December 2020

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis

1 reference

12 December 2020

Effects of Intermittent Parathyroid Hormone Administration on Bone Mineralization Density in Iliac Crest Biopsies from Patients with Osteoporosis: A Paired Study before and after Treatment

1 reference

12 December 2020

Alendronate for the Treatment of Osteoporosis in Men

1 reference

12 December 2020

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

12 December 2020

Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis

1 reference

12 December 2020

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

1 reference

12 December 2020

Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial

1 reference

12 December 2020

Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies

1 reference

12 December 2020

Antifracture efficacy of antiresorptive agents are related to changes in bone density.

1 reference

12 December 2020

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

1 reference

12 December 2020

A theoretical analysis of the contributions of remodeling space, mineralization, and bone balance to changes in bone mineral density during alendronate treatment.

1 reference

12 December 2020

The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change.

1 reference

12 December 2020

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

12 December 2020

Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women

1 reference

12 December 2020

Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate

1 reference

12 December 2020